Xiaomin Fan

Xiaomin Fan is a biotechnology professional with over 15 years of experience. Xiaomin started their career in 2001 as a Senior Scientist and Group Leader at Targeted Molecules Corp, where they developed and optimized in vivo phage display technology and conceptualized and developed an in vivo method to study kinetic structure activity relationship of peptide ligands. Xiaomin also organized and executed efforts to isolate 3 peptide leads that selectively target organs of interest, including brain and kidney. In 2006, Xiaomin founded AvantGen, Inc., a San Diego-based biotechnology company with therapeutic and bioscience divisions. As the President of AvantGen, they are dedicated to novel human antibody discovery, antibody humanization, antibody affinity maturation and optimization, for therapeutic development as well as discovery of antibodies with novel formats for immunotherapy. Xiaomin also collaborates with pharmaceutical and biotechnology companies to facilitate and speed their path to antibody-based therapeutic development through services, partnerships, and licensing.

Xiaomin Fan attended The University of Kansas from 1992 to 1996, where they obtained their Ph.D. in Biochemistry/Molecular Biology. Xiaomin then attended the University of Pennsylvania School of Medicine from 1996 to 2000, where they studied Pharmacology.